Cullinan Therapeutics (CGEM) said Tuesday that it is starting a US study of CLN-978 in patients with Sjogren's disease, a chronic autoimmune disease.
The company said it will enroll patients with active, moderate to severe disease fulfilling the 2016 American College of Rheumatology classification criteria and who are positive for anti-Sjogren's syndrome-related antigen A/Ro antibodies and/or rheumatoid factor.
The study will evaluate the safety and tolerability of CLN-978, while secondary objectives include pharmacokinetics, pharmacodynamics, immunogenicity, and effect on disease activity, according to Cullinan.
The company said it expects to start the study in Q2.
Shares of Cullinan were up 2.4% in recent trading.
Price: 7.94, Change: +0.19, Percent Change: +2.39
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.